Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Moderna raises $560mm in Series G round

Executive Summary

Moderna Therapeutics LLC (mRNA therapeutics) raised $560mm in its Series G financing round consisting of 55.7mm preferred shares at $10.06. New US and international investors Abu Dhabi Investment Authority, BB Biotech AG, Julius Baer, Singapore-based EDBI, and Sequoia Capital China joined existing investors Fidelity Management & Research, Pictet, Viking Global Investors, ArrowMark Partners, and Alexandria Venture Investments. The company will use the funds to continue to execute on its pipeline (19 development candidates including 10 in clinical trials); for drug discovery in rare diseases and prophylactic vaccines; for investment in mRNA science and technology; and for investment in manufacturing infrastructure and digital backbone.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
      • Pulmonary
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies